# COMPEL (NCT04765059)

> A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04765059
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer
- Interventions: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Enrollment: 98
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on COMPEL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=compel-nct04765059